Drug intelligence / Profile preview

wogonoside

Development stage
Preclinical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration
Oral (experimental), Intraperitoneal (experimental, Mice)
01

Overview

Wogonoside is a naturally occurring flavonoid glycoside, specifically the 7-O-glucuronide of wogonin, primarily found in traditional Chinese medicinal plants such as Scutellaria baicalensis. It exhibits potent **antitumor**, **anti-inflammatory**, **anticoagulant**, **anti-angiogenic**, and **antioxidant** activities. Mechanistically, wogonoside induces apoptosis via mitochondrial pathways (upregulation of Bax, downregulation of Bcl-2, activation of caspase-3/9), triggers endoplasmic reticulum (ER) stress-mediated cell death via activation of the IRE1α-TRAF2-ASK1 complex and the JNK pathway, and suppresses PI3K/Akt/mTOR/p70S6K signaling. It strongly inhibits angiogenesis by blocking vascular endothelial growth factor (VEGF) expression and Hedgehog signaling through Smoothened degradation, and may reduce inflammation by dual inhibition of NF-κB and the NLRP3 inflammasome. Wogonoside is being investigated as a lead compound for cancer therapy, especially in gastric, colon, and triple-negative breast cancers.

Other names
Wogonin 7-glucuronideWogonin7-glucuronideWogonin-7-glucuronideWogonin 7-β-D-glucuronideWogonin 7-O-β-D-glucuronideGlychionide BOroxindin5,7-Dihydroxy 8-methoxyflavone 7-glucuronide
02

Targets

BAX (Apoptosis regulator BAX)CASP3 (Caspase-3)CASP9 (Caspase-9)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)mTOR (Mammalian target of rapamycin kinase)RPS6KB1 (Ribosomal protein S6 kinase beta-1)MAP3K5 (ASK1)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NF-κBAKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)ERN1 (Inositol-requiring enzyme 1 alpha)SMO (Smoothened)TRAF2VEGFA (Vascular endothelial growth factor A)JNK (Mitogen-activated protein kinase kinase kinase family)

Beyond the preview

Go deeper on wogonoside.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on wogonoside.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call